EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

Active: 2008–2026

Contract Awards

$2.70B

18 awards

Summary

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. is an organization. Its political footprint includes $2.70 billion in government contracts. Their largest government contract source is Department of Health and Human Services at $2.69 billion. Political activity spans from 2008 to 2026.

Cross-Source Financial Activity

These are different money flows and are not added together: contributions and lobbying expenses flow out, while contract awards flow to the organization.

Contract awards $2.70B

Political Money Flow

How Money Flows

Government agencies → EMERGENT PRODUCT DEVEL... (contracts) → political recipients & lobbying. Hover for details.

Contracts by Agency

2 agencies

#	Agency	Total Awarded	Awards
1	Department of Health and Human Services	$2.69B	16
2	Department of Defense	$15.5M	2

Individual Awards

16 awards (top by amount)

Date	Agency	Description	Amount	NAICS
2025-08-29	Department of Health and Human Services	EO14042 EMERGENT AV7909 ANTHRAX VACCINE	$1.39B	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2026-06-26	Department of Health and Human Services	ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM)	$857.6M	BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
2026-02-05	Department of Health and Human Services	THE PURPOSE OF THIS NO-COST MODIFICATION IS TO UPDATE SEVERAL ARTICLES.	$118.6M	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
2022-07-01	Department of Health and Human Services	EMERGENT HAS SUBMITTED A CLAIM OF $8,047,678.58 AGAINST CONTRACT NUMBER HHSO100201000059C ON MARCH 30TH, 2022. THE CONTRACTING OFFICE HAS REVIEWED THE CLAIM LETTER AND THE INDIRECT COST NEGOTIATION AGREEMENT BETWEEN EMERGENT AND THE NATIONAL INSTITUT	$93.0M	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2024-09-11	Department of Health and Human Services	ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909	$43.8M	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2020-09-18	Department of Health and Human Services	DEVELOPMENT OF TECHNOLOGIES TO FACILITATE THE USE OF , AND RESPONSE TO BIODEFENSE VACCINES THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE REMAINING FUNDS AND CLOSE THE CONTRACT	$38.0M	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2024-04-26	Department of Health and Human Services	EXTEND CONTRACT TO ALLOW DELIVERY OF PHASE 1 CLINICAL STUDY REPORT	$33.0M	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2023-03-13	Department of Health and Human Services	DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS	$30.2M	RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
2021-06-08	Department of Health and Human Services	FUNDING ACTION ONLY	$26.7M	RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
2021-06-10	Department of Health and Human Services	AVP-21D9 ANTHRAX MONOCLONAL ANTIBODY	$18.1M	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2019-03-13	Department of Health and Human Services	DILUENT REPLACEMENT	$12.2M	BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
2021-09-01	Department of Health and Human Services	DEVELOPMENT OF THERAPEUTICS AGENTS FOR SELECTED BIODEFENSE.	$12.2M	RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES
2024-07-17	Department of Defense	ANALGESIC KETAMINE-CLINICAL TRIAL	$5.7M	RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
2013-09-17	Department of Health and Human Services	IGF::OT::IGF -- TASK ORDER TO EMERGENT PRODUCT DEVEOPMENT DELIVERY OF MASTER CELL BANK VIALS TO THE USG FOR THE FUTURE PRODUCTION OF ANTHRAX ANTITOXIN HHSO100201300011I	$353K	PHARMACEUTICAL PREPARATION MANUFACTURING
2013-09-06	Department of Health and Human Services	IGF::OT::IGF	$100K	PHARMACEUTICAL PREPARATION MANUFACTURING
2026-04-28	Department of Health and Human Services	HIV BIOLOGICS MASTER FILE SUPPORT POP: 4/27/26 TO 3/31/27, EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC.	$11K	RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Activity data: USAspending.gov

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. — Contributions, Lobbying & Contracts | Poliscope